Research Topics
| Jane L LiesveldSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Management of AML: who do we really cure?Jane Liesveld
Hematology Oncology, JP Wilmot Cancer Center, University of Rochester Medical Center Strong Memorial Hospital, Rochester, NY 14642, USA
Leuk Res 36:1475-80. 2012....
Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cellsJane L Liesveld
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Leuk Res 31:1553-63. 2007..This work confirms that AML is influenced by the SDF-1alpha/CXCR4 axis and demonstrates that disruption of this axis by the bicyclam AMD3100 can influence AML microenvironmental interactions...
Flavonoid effects on normal and leukemic cellsJane L Liesveld
Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
Leuk Res 27:517-27. 2003..These flavonoid compounds might find use in various therapeutic settings in AML...- Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipientsJane L Liesveld
Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
Biol Blood Marrow Transplant 8:662-5. 2002..This study demonstrates the feasibility and significant cost savings of using oral VAL for HSV prophylaxis... - The hematopoietic stem cell in myelodysplasiaJane L Liesveld
Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
Stem Cells 22:590-9. 2004.... - Mixed chimerism in SCT: conflict or peaceful coexistence?J L Liesveld
Department of Medicine, The James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
Bone Marrow Transplant 42:297-310. 2008.... - Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activationJ L Liesveld
Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
J Hematother Stem Cell Res 10:643-55. 2001..Further understanding of this process may help elucidate the mechanism of stem cell mobilization and homing... - MIP-1alpha and TGF-beta production in CD34+ progenitor-stromal cell coculture systems: effects of progenitor isolation method and cell-cell contactJ L Liesveld
Department of Medicine, University of Rochester Cancer Center, Rochester, New York 14642, USA
Blood Cells Mol Dis 26:261-75. 2000..The method of isolation of CD34+ progenitors may influence secretion of certain cytokines and chemokines... - Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell linesJane L Liesveld
Department of Medicine, Hematology Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA jane
Cancer Invest 29:439-50. 2011..Combinations with arsenic trioxide, sorafenib, and cytarabine demonstrated synergistic in vitro effects in AML cell lines... - Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataDuane C Hassane
James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
Blood 111:5654-62. 2008..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets... - Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AMLAlison R Walker
James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
Leuk Res 32:1830-6. 2008..To assess the efficacy of imatinib mesylate in combination with CLAG, a larger phase II trial is now planned... - Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and E-selectinKuldeepsinh Rana
Department of Biomedical Engineering, Cornell University, Ithaca, New York, USA
Biotechnol Bioeng 102:1692-702. 2009..This represents the first demonstration of a novel biomimetic method to capture metastatic cells from circulation and deliver an apoptotic signal... - A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotectionGordon L Phillips
Hematology Oncology, University of Rochester Medical Center, James P Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA
Biol Blood Marrow Transplant 17:1033-42. 2011..A Phase II trial is planned... - P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrowSrinivas D Narasipura
Department of Biomedical Engineering, Wilmot Cancer Center, University of Rochester, Rochester, NY 14627, USA
Clin Chem 54:77-85. 2008..We have exploited this differential rolling behavior to capture and purify HSPCs from bone marrow by perfusing MNCs through selectin-coated microtubes... - Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibitionJane L Liesveld
University of Rochester, University of Rochester Medical Center, Department of Medicine and the James P. Wilmot Cancer Center, Rochester, NY 14642, USA
Hematology 10:483-94. 2005..These studies demonstrate that AML is subject to influence of endothelial cells and of agents such as bortezomib which have potential impact on AML interaction with the microenvironmental niche... - An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4427-35. 2007..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo... - Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Monica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4436-44. 2007..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations... - Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemiaTodd S Laughlin
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
J Mol Diagn 10:338-45. 2008..Using a 100 nmol/L concentration of the LNA clamp, NPM1 mutations were detectable in a 10-fold excess of wild-type DNA. This assay may be valuable for screening disease specimens... - Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulinMartin S Zand
Division of Nephrology, University of Rochester Medical Center, 601 Elmwood Ave, Box 675, Rochester, NY 14642, USA
Blood 107:2895-903. 2006..We conclude that rATG is an effective agent for in vitro induction of apoptosis in multiple myeloma, and that exploratory clinical trials may be warranted... - TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursorsJ Tang
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
J Immunol 159:117-25. 1997..These results indicate that TGF-beta is a significant negative regulator of stroma-dependent proliferation of early human lymphoid progenitors and acts in part by down-regulating stromal IL-7 secretion... - Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group StudyJ M Bennett
University of Rochester Cancer Center, New York 14642, USA
Am J Hematol 66:23-7. 2001..55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients... - Stem cell factor and stromal cell co-culture prevent apoptosis in a subculture of the megakaryoblastic cell line, UT-7J L Liesveld
Department of Medicine, University of Rochester School of Medicine, NY 14642, USA
Leuk Res 20:591-600. 1996.... - Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patientsChristine M Szych
Department of Pathology, University of Rochester, Strong Memorial Hospital, 601 Elmwood Avenue, P O Box 704, Rochester, NY 14642, USA
Cancer Genet Cytogenet 174:132-7. 2007..The impact of the isodicentric Philadelphia chromosomes on genomic instability, heterogeneity, and amplification of the Philadelphia chromosomes in IM-resistant patients is discussed... - Investigating the feasibility of stem cell enrichment mediated by immobilized selectinsNichola Charles
Department of Biomedical Engineering, University of Rochester, Rochester, New York, USA
Biotechnol Prog 23:1463-72. 2007..Optimal cell enrichment in immobilized selectin surfaces can be achieved within 10 min, much faster than most current commercially available systems... - Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term cultureNicki Panoskaltsis
The University of Rochester Medical Center, Department of Internal Medicine, Hematology Oncology Unit, Box 610, Rochester, NY 14642, USA
Leuk Res 26:191-201. 2002..Optimal growth and DC characteristics were obtained with GM-CSF, FL, and SCF in 3-5 day cultures, suggesting a practical strategy for the immunotherapy of leukemia... - Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulinJ T Horan
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Bone Marrow Transplant 35:171-7. 2005.... - Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesisJ L Liesveld
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Leukemia 17:1806-12. 2003..These data suggest that myelosuppression with R115777 occurs largely at the intermediate to late progenitor stage of hematopoiesis and that cyclic use might avoid long-term marrow suppression... - Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantationS Q Fu
Blood and Marrow Stem Cell Transplant Program, Department of Internal Medicine and The James P. Wilmot Cancer Center, University of Rochester, New York 14642, USA
Blood Cells Mol Dis 28:315-21. 2002..The CFU-GM/CD34+ ratio is an apparent predictor of earlier platelet engraftment, suggesting that the ratio reflects the engraftment potential of mobilized donor progenitor cells... - The effect of using music therapy with relaxation imagery in the management of patients undergoing bone marrow transplantation: a pilot feasibility studyOlle Jane Z Sahler
University of Rochester Medical Center, USA
Altern Ther Health Med 9:70-4. 2003..MAIN OUTCOME MEASURES: Pre/post music/relaxation imagery intervention measures of pain and nausea using a visual analog scale; determination of time-to-engraftment... - Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphomaSughosh Dhakal
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Radiat Oncol Biol Phys 75:188-92. 2009.... - Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trialsJ T Horan
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Bone Marrow Transplant 32:293-8. 2003..07 for the studies enrolling a smaller proportion. This finding substantiates results from previously published studies that have demonstrated a survival advantage with PBSCT limited to patients with advanced disease... - Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary reportG L Phillips
The James P. Wilmot Cancer Center, BMT Program, Rochester, NY 14642, USA
Semin Oncol 31:59-61. 2004..Patient entry at the starting dose (ie, HD-MEL 140 mg/m2) has been completed without the development of severe regimen-related toxicities. This trial is ongoing... - What would Karl Landsteiner do? The ABO blood group and stem cell transplantationJ M Heal
Hematology Oncology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Bone Marrow Transplant 36:747-55. 2005.... - Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplantsA P Rapoport
University of Rochester Medical Center, Rochester, NY
J Clin Oncol 17:2446-53. 1999..To identify predictors of oral mucositis and gastrointestinal toxicity after high-dose therapy... - The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF aloneNeal Flomenberg
Thomas Jefferson University, 125 S Ninth St, Ste 801 Sheridan Bldg, Philadelphia, PA 19107, USA
Blood 106:1867-74. 2005..All study objectives were met without significant toxicity. The results demonstrate that the combination of A + G is generally safe, effective, and superior to G alone for autologous HPC mobilization... - Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 112:3500-7. 2008..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT... - Acute promyelocytic leukemia-mobile and infiltrativeJane L Liesveld
Leuk Res 31:5-7. 2007 - A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupJacob M Rowe
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Haifa 31096 Israel
Blood 103:479-85. 2004..Priming with hematopoietic growth factor did not improve response when compared with placebo. Furthermore, delaying induction therapy in older adults may lead to a lower complete remission rate... - A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
Blood 109:1387-94. 2007..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response... - A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeCorey S Cutler
International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226, USA
Blood 104:579-85. 2004..For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy...
Research Grants
- Proteasome Inhibition in Myelodysplastic SyndromesJane Liesveld; Fiscal Year: 2006..These studies will define a potential therapeutic role for bortezomib in MDS and will aid in understanding the hematopoietic stem cell in these disorders. ..